Skip to main content

Closed

CANF: Can-Fite BioPharma Ltd. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Revenue growth-39.4% / yr

Operating margin-2456.8%

ROIC-145.5%

Financially safe

Stretched

Debt / equity0.01×

Interest coverage0.0×

Current ratio3.46×

Can-Fite BioPharma Ltd.

CANFNew York Stock Exchange Arca·USD·Closed

Can-Fite BioPharma Ltd.

CANFNew York Stock Exchange Arca·USD·Closed

$3.19

+0.63%

$3.19

+$0.02 (0.63%)

52W Range

6thpctl

Volume

0.02×avg

Mkt Cap

1.72MUSD

P/E

-0.7TTM

Div Yield

–ann

52W Range

6thpctl

Volume

0.02×avg

Market Cap

1.72MUSD

P/E Ratio

-0.7TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings